Shield Diagnostics

Shield Diagnostics is a private infectious-disease diagnostics company and clinical laboratory focused on combating antibiotic resistance through rapid molecular testing. The company has described its mission as enabling resistance-guided therapy, with an initial commercial product, Target-NG, designed to determine ciprofloxacin susceptibility in Neisseria gonorrhoeae. Shield operated a CLIA- and CAP-accredited laboratory in San Jose, California and promoted a 24-hour turnaround time for gonorrhea reflex susceptibility testing. The business appears to have been backed by prominent venture investors including Andreessen Horowitz and has also been referred to publicly as Shield Bio. Available public information suggests a narrow commercial diagnostics focus rather than a broad therapeutic pipeline.